Insights - Top-line results from Ohr Pharmaceuticals’ (OHRP) phase II IMPACT study, testing its squalamine eyedrops in age-related macular degeneration (wet-AMD), had a crushing effect on the stock Friday. … Continue Reading
Read nowInsights - Esperion Therapeutics, Inc. (ESPR) on released positive Phase 2b results for ETC-1002, its novel, oral cholesterol lowering therapy.
Read nowInsights - The big news this weekend out of the American College of Cardiology's annual scientific session was the comparison of long-term outcomes for two new (and competing) drugs targeting cholesterol,
Read nowResearch - SAGE Therapeutics (SAGE) and Marinus Pharmaceuticals (MRNS)are innovators in a class of molecules known as neurosteroids and both target epilepsy initially.
PremiumInsights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read nowResearch - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read nowRecap - We’re in the throes of yet another sharp “V-bottom” for the S&P 500 (SPX), a rapid drop followed by a rip-your-face off rally – the 10th occurrence … Continue Reading
Read now
